Uptake

Canaccord Genuity Acts as Financial Adviser to Uptake on its Acquisition by Prescient

Canaccord Genuity is pleased to announce that it has advised Uptake (Uptake Strategies Ltd), a global healthcare consultancy, on its acquisition by Prescient (Prescient Healthcare Group), an international consulting partner to the biopharmaceutical industry.

The acquisition brings together two like-minded organisations with a focus on exceptional client delivery and impact in the pharmaceutical and biotech industry. This strategic move marks the beginning of an exciting new chapter for both companies, combining complementary expertise and shared values to deliver exceptional impact for pharmaceutical and biotech clients and the patients they serve worldwide.

Prescient is an international consulting partner to the biopharmaceutical industry, with offices in the US, UK, India, Spain, and Germany. The company operates across three core practices: Medical, led by Luke Solon, Competitive Strategy, led by Ryan Caradonna, and a newly combined Commercial Practice, which will be co-led by Prescient’s Simon Campling and Uptake’s Managing Director, Maxine Smith. Stephanie Hall, CEO and Founder of Uptake, will assume the role of Global Practice Lead - Commercial and join the Prescient Board, ensuring continuity of Uptake’s values, culture, and dedication to delivering exceptional performance for clients throughout the integration.

Together, Prescient and Uptake will combine global scale and deep expertise, to deliver transformative solutions for pharma and biotech clients, and better outcomes for patients worldwide.

The transaction is supported by Prescient’s existing investment partner Bridgepoint, which partnered with the company in 2021 via Bridgepoint Development Capital, a lower middle-market fund focused on supporting fast-growing businesses across Europe.